Policy Analysis: Life Sciences
Horizon 2020 Special Coverage
The 2015 Science|Business Annual Summit
The Science|Business Annual Summit brings together leaders from research, industry and policy to debate current and future trends needed to unleash Europe’s technological potential.
Barcelona - 17 November 2015
The future of manufacturing: Industry 4.0
A Science|Business public conference
Brussels - 01 October 2015
The Bioeconomy Challenge: Producing more from less
A Science|Business high-level roundtable
Brussels - 02 July 2015
The new European Commission: Bad news for research and innovation?
Advocates for cross-sectoral R&D support fear a downgrade in the new Commission – but in individual areas such as energy, digital technologies, and pharmaceuticals, a stronger emphasis on growth and investment is good news for many
Published:
Domain Therapeutics and Merck Serono to collaborate on Parkinson’s disease drug


Domain Therapeutics today announced that an exclusive development and licensing agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, was signed to develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease and other neurodegenerative diseases.

Domain Therapeutics will contribute optimized compounds that have been developed from its proprietary chemical series. Under the terms of the agreement, the company will receive EUR 2 million in upfront payment and research funding, and...



Related subjects: Parkinson’s disease

Advertisement